Pharmacodynamic effects of cangrelor and clopidogrel: The platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials

Journal of Thrombosis and Thrombolysis

Volumn 34, Issue 1, 2012, Pages 44-55

  Angiolillo, Dominick J ^a   Schneider, David J ^b   Bhatt, Deepak L ^c   French, William J ^d   Price, Matthew J ^e   Saucedo, Jorge F ^f   Shaburishvili, Tamaz ^g   Huber, Kurt ^h   Prats, Jayne ⁱ   Liu, Tiepu ⁱ   Harrington, Robert A ^j   Becker, Richard C ^j  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e SCRIPPS CLINIC   (United States)

^f UNIVERSITY OF OKLAHOMA   (United States)

^g Diagnostic Services Clinic   (Georgia)

^h WILHELMINEN HOSPITAL   (Austria)

ⁱ MEDICINES COMPANY   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Cangrelor; Clopidogrel; PCI; Platelet function

Indexed keywords

ADENOSINE DIPHOSPHATE; CANGRELOR; CLOPIDOGREL; PLACEBO; PURINERGIC P2Y12 RECEPTOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ASSAY; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; UNSTABLE ANGINA PECTORIS;

ADENOSINE MONOPHOSPHATE; AGED; ANGIOPLASTY, BALLOON, CORONARY; DRUG ANTAGONISM; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; TICLOPIDINE;

EID: 84862772806     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0737-3     Document Type: Article

References (30)

1. GN Levine ER Bates JC Blankenship SR Bailey JA Bittl B Cercek CE Chambers SG Ellis RA Guyton SM Hollenberg UN Khot RA Lange L Mauri R Mehran ID Moussa D Mukherjee BK Nallamothu 2011 American college of cardiology foundation; American heart association task force on practice guidelines; society for cardiovascular angiography and interventions. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions J Am Coll Cardiol 58 e44 e122 22070834 10.1016/j.jacc.2011.08.007
2. DJ Angiolillo A Fernandez-Ortiz E Bernardo F Alfonso C Macaya TA Bass MA Costa 2007 Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 1505 1516 17418288 10.1016/j.jacc.2006.11.044 1:CAS:528:DC%2BD2sXjvFGgt7s%3D
3. L Bonello US Tantry R Marcucci R Blindt DJ Angiolillo R Becker DL Bhatt M Cattaneo JP Collet T Cuisset C Gachet G Montalescot LK Jennings D Kereiakes D Sibbing D Trenk JW Van Werkum F Paganelli MJ Price R Waksman 2010 Working group on high on-treatment platelet reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to ADP J Am Coll Cardiol 56 919 933 20828644 10.1016/j.jacc.2010.04.047 1:CAS:528:DC%2BC3cXhtlWjt7jJ
4. JL Ferreiro D Sibbing DJ Angiolillo 2010 Platelet function testing and risk of bleeding complications Thromb Haemost 103 1128 1135 20352168 10.1160/TH09-11-0799 1:CAS:528:DC%2BC3cXovF2kurg%3D
5. D Sibbing SR Steinhubl S Schulz A Schömig A Kastrati 2010 Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window J Am Coll Cardiol 56 317 318 20633826 10.1016/j.jacc.2010.03.048
6. G Patti V Pasceri V Vizzi E Ricottini G Di Sciascio 2011 Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the antiplatelet therapy for reduction of myocardial damage during angioplasty-bleeding study) Am J Cardiol 107 995 1000 21256470 10.1016/j.amjcard.2010.11.025
7. S Matetzky B Shenkman V Guetta M Shechter R Beinart I Goldenberg I Novikov H Pres N Savion D Varon H Hod 2004 Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 3171 3175 15184279 10.1161/01.CIR. 0000130846.46168.03 1:CAS:528:DC%2BD2cXltVCgtro%3D
8. W Hochholzer D Trenk HP Bestehorn B Fischer CM Valina M Ferenc M Gick A Caputo HJ Büttner FJ Neumann 2006 Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement J Am Coll Cardiol 48 1742 1750 17084243 10.1016/j.jacc.2006.06.065 1:CAS:528:DC%2BD28XhtFOjtb7E
9. MJ Price S Endemann RR Gollapudi R Valencia CT Stinis JP Levisay A Ernst NS Sawhney RA Schatz PS Teirstein 2008 Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 992 1000 18263931 10.1093/eurheartj/ehn046
10. G Patti A Nusca F Mangiacapra L Gatto A D'Ambrosio G Di Sciascio 2008 Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (antiplatelet therapy for reduction of myocardial damage during angioplasty-platelet reactivity predicts outcome) study J Am Coll Cardiol 52 1128 1133 18804738 10.1016/j.jacc.2008.06.038 1:CAS:528:DC%2BD1cXhtFersr7I
11. R Marcucci AM Gori R Paniccia B Giusti S Valente C Giglioli P Buonamici D Antoniucci R Abbate GF Gensini 2009 Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12 month follow-up Circulation 119 237 342 19118249 10.1161/CIRCULATIONAHA.108.812636
12. D Sibbing S Braun T Morath J Mehilli W Vogt A Schömig A Kastrati N von Beckerath 2009 Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis J Am Coll Cardiol 53 849 856 19264241 10.1016/j.jacc.2008.11.030 1:CAS:528: DC%2BD1MXlslagsrk%3D
13. NJ Breet JW van Werkum HJ Bouman JC Kelder HJ Ruven ET Bal VH Deneer AM Harmsze JA van der Heyden BJ Rensing MJ Suttorp CM Hackeng JM ten Berg 2010 Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 754 762 20179285 10.1001/jama.2010.181 1:CAS:528:DC%2BC3cXisFyisbw%3D
14. SD Wiviott E Braunwald CH McCabe G Montalescot W Ruzyllo S Gottlieb FJ Neumann D Ardissino S De Servi SA Murphy J Riesmeyer G Weerakkody CM Gibson TRITON-TIMI 38 Investigators 2007 Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2001 2015 17982182 10.1056/NEJMoa0706482 1:CAS:528:DC%2BD2sXhtlWis7rN
15. L Wallentin RC Becker A Budaj CP Cannon H Emanuelsson C Held J Horrow S Husted S James H Katus KW Mahaffey BM Scirica A Skene PG Steg RF Storey PLATO Investigators A Freij M Thorsén 2009 Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 1045 1057 19717846 10.1056/NEJMoa0904327 1:CAS:528:DC%2BD1MXhtFaltL%2FJ
16. SR Mehta JF Tanguay JW Eikelboom SS Jolly CD Joyner CB Granger DP Faxon HJ Rupprecht A Budaj A Avezum P Widimsky PG Steg JP Bassand G Montalescot C Macaya G Di Pasquale K Niemela AE Ajani HD White S Chrolavicius P Gao KA Fox CURRENT-OASIS 7 Trial Investigators 2010 Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 376 1233 1243 20817281 10.1016/S0140-6736(10)61088-4 1:CAS:528:DC%2BC3cXht1KrsbbE
17. JL Ferreiro M Ueno DJ Angiolillo 2009 Cangrelor: a review on its mechanism of action and clinical development Expert Rev Cardiovasc Ther 7 1195 1201 19814662 10.1586/erc.09.101 1:CAS:528:DC%2BD1MXht1Cmt7nN
18. RA Harrington GW Stone S McNulty HD White AM Lincoff CM Gibson CV Pollack Jr G Montalescot KW Mahaffey NS Kleiman SG Goodman M Amine DJ Angiolillo RC Becker DP Chew WJ French F Leisch KH Parikh S Skerjanec DL Bhatt 2009 Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2318 2329 19915221 10.1056/NEJMoa0908628 1:CAS:528:DC%2BD1MXhsFGlsbfF
19. DL Bhatt AM Lincoff CM Gibson GW Stone S McNulty G Montalescot NS Kleiman SG Goodman HD White KW Mahaffey CV Pollack Jr SV Manoukian P Widimsky DP Chew F Cura I Manukov F Tousek MZ Jafar J Arneja S Skerjanec RA Harrington CHAMPION PLATFORM Investigators 2009 Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2330 2341 19915222 10.1056/NEJMoa0908629 1:CAS:528:DC%2BD1MXhsFGltr7P
20. SR Steinhubl JJ Oh JH Oestreich S Ferraris R Charnigo WS Akers 2008 Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect Thromb Res 121 527 534 17631948 10.1016/j.thromres.2007. 05.020 1:CAS:528:DC%2BD1cXhsFylsr8%3D
21. NL Dovlatova JA Jakubowski A Sugidachi S Heptinstall 2008 The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function J Thromb Haemost 6 1153 1159 18485086 10.1111/j.1538-7836.2008.03020.x 1:CAS:528:DC%2BD1cXpt1ahsbw%3D
22. DJ Schneider BE Sobel 2009 Streamlining the design of promising clinical trials: in vitro testing of antithrombotic regimens and multiple agonists of platelet activation Coron Artery Dis 20 175 178 19194284 10.1097/MCA. 0b013e32831edcd1
23. JA Jakubowski YG Li DS Small CD Payne ME Tomlin J Luo KJ Winters 2010 A comparison of VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis J Cardiovasc Pharmacol 56 29 37 20386460 10.1097/FJC.0b013e3181dd0ec2 1:CAS:528:DC%2BC3cXovFSlt7w%3D
24. EJ Topol DJ Moliterno HC Herrmann ER Powers CL Grines DJ Cohen EA Cohen M Bertrand FJ Neumann GW Stone PM DiBattiste TARGET Investigators 2001 Do tirofiban and reopro give similar efficacy trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization N Engl J Med 344 1888 1894 11419425 10.1056/NEJM200106213442502 1:CAS:528:DC%2BD3MXltFers7o%3D
25. SS Kabbani A Aggarwal EF Terrien PM DiBattiste BE Sobel DJ Schneider 2002 Suboptimal early inhibition of platelets by treatment with tirofiban: implications for coronary interventions Am J Cardiol 89 547 550 10.1016/S0002-9149(01)02319-0
26. +2 on GP IIb-IIIa interactions with integrelin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in concentration of ionized calcium in plasma anticoagulated with citrate Circulation 96 1488 1494 9315536 10.1161/01.CIR.96.5.1488 1:CAS:528: DyaK2sXmtFeis7g%3D
27. DJ Schneider HC Herrmann N Lakkis F Aguirre M-W Lo A Aggarwal SS Kabbani PM DiBattiste 2003 Association of greater bolus doses with increased concentrations of tirofiban in blood and correlation with the inhibition of platelet aggregation Am J Cardiol 91 334 336 12565092 10.1016/S0002-9149(02) 03163-6 1:CAS:528:DC%2BD3sXmsFWluw%3D%3D
28. PA Gurbel KP Bliden K Butler US Tantry T Gesheff C Wei R Teng MJ Antonino SB Patil A Karunakaran DJ Kereiakes C Parris D Purdy V Wilson GS Ledley RF Storey 2009 Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study Circulation 120 2577 2585 19923168 10.1161/CIRCULATIONAHA.109.912550 1:CAS:528:DC%2BD1MXhsFGgtb3N
29. DJ Angiolillo MS Firstenberg MJ Price PE Tummala M Hutyra IJ Welsby MD Voeltz H Chandna C Ramaiah M Brtko L Cannon C Dyke T Liu G Montalescot SV Manoukian J Prats BRIDGE Investigators 2012 Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial JAMA 307 265 274 22253393 10.1001/jama.2011.2002 1:CAS:528:DC%2BC38Xht1equrw%3D
30. HD White DP Chew HL Dauerman KW Mahaffey CM Gibson GW Stone L Gruberg RA Harrington DL Bhatt 2012 Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction Am Heart J 163 182 190 22305835 10.1016/j.ahj.2011.11.001